Tiger Jade Capital
Overview
Tiger Jade Capital is a healthcare-focused private equity firm founded in 2019, backed by Chinese CRO company Tigermed . The firm focuses on venture opportunities and mainly invests in the healthcare industry in China, covering new drugs, CRO, medical equipment, etc . Tiger Jade Capital aspires to aggregate conscious capital to improve people's well being and contribute to the community with total dedication and integrity; and as a result, deliver optimal returns for its investors .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Abogen Biosciences | Aug 2021 | Series C | Co-investor |
| Guangzhou Yinming Biomedical Technology | Sep 2021 | Series A Extension | Co-investor |
| Spot Biosystems | Jun 2026 | VC Round | Co-investor |
| Great Bay Bio | Sep 2022 | Series B | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Tiger Jade Capital based?
Tiger Jade Capital is headquartered in Hong Kong, Hong Kong, Hong Kong.
When was Tiger Jade Capital founded?
Tiger Jade Capital was founded in 2019.
How many portfolio companies does Tiger Jade Capital have?
Tiger Jade Capital has 4 portfolio companies in Caplight's dataset.
What are some companies in Tiger Jade Capital's portfolio?
Portfolio companies visible on Caplight include Abogen Biosciences, Guangzhou Yinming Biomedical Technology, Spot Biosystems, Great Bay Bio.
What was Tiger Jade Capital's most recent investment shown here?
Tiger Jade Capital's most recent investment in this portfolio sample was in Spot Biosystems in 2026.
What sectors does Tiger Jade Capital focus on?
Tiger Jade Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, AI, Data & Cloud Infrastructure.
What company stages does Tiger Jade Capital focus on?
Tiger Jade Capital typically invests at the Mid stage.
What is Tiger Jade Capital's AUM?
Tiger Jade Capital's assets under management are estimated between $100.0M and $250.0M.